- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-182/17: Action brought on 20 March 2017 — Novartis v EUIPO — Chiesi Farmaceutici (AKANTO)
ECLI:EU:UNKNOWN:62017TN0182
62017TN0182
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
22.5.2017
EN
Official Journal of the European Union
C 161/32
(Case T-182/17)
(2017/C 161/46)
Language in which the application was lodged: English
Parties
Applicant: Novartis AG (Basel, Suisse) (represented by: L. Junquera Lara, lawyer)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Chiesi Farmaceutici SpA (Parma, Italy)
Details of the proceedings before EUIPO
Applicant of the trade mark at issue: Applicant
Trade mark at issue: EU word mark ‘AKANTO’ — Application for registration No 13 289 781
Procedure before EUIPO: Opposition proceedings
Contested decision: Decision of the First Board of Appeal of EUIPO of 9 January 2017 in Case R 531/2016-1
Form of order sought
The applicant claims that the Court should:
—annul the contested decision;
—declare that Article 8(1)(b) of Regulation No 207/2009 does not preclude the sign at issue (European trade mark No 13 289 781) in respect of the goods in class 5 described in the application for registration;
—order EUIPO to pay the costs.
Plea in law
—Infringement of Article 8(1)(b) of Regulation No 207/2009.